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Abstract
Graves’ orbitopathy (GO) is a disfiguring and sometimes blinding disease, characterised by inflammation and swelling of
orbital tissues, with fibrosis and adipogenesis being predominant features. Little is known about the disease aetiology and
the molecular mechanisms driving the phenotypic changes in orbital fibroblasts are unknown. Using fibroblasts isolated
from the orbital fat of undiseased individuals or GO patients, we have established a novel in vitromodel to evaluate the dual
profile of GO cells in a three-dimensional collagen matrix; this pseudo-physiological 3D environment allows measurement of
their contractile and adipogenic properties. GO cells contracted collagen matrices more efficiently than control cells
following serum or TGFb1 stimulation, and showed a slightly increased ability to proliferate in the 3D matrix, in accordance
with a fibro-proliferative phenotype. GO cells, unlike controls, also spontaneously differentiated into adipocytes in 3D
cultures - confirming an intrinsic adipogenic profile. However, both control and GO cells underwent adipogenesis when
cultured under pathological pressure levels. We further demonstrate that a Thy-1-low population of GO cells underlies the
adipogenic - but not the contractile - phenotype and, using inhibitors, confirm that the contractile and adipogenic
phenotypes are regulated by separate pathways. In view of the current lack of suitable treatment for GO, we propose that
this new model testing the duality of the GO phenotype could be useful as a preclinical evaluation for the efficacy of
potential treatments.
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Introduction
Graves’ Orbitopathy (GO) is a common manifestation that
affects up to 50% of patients with autoimmune thyroid disease [1].
The morbidity of GO is largely related to orbital fat expansion,
this resulting from several pathological processes including
adipogenesis, hyaluronan secretion and fibrosis [2–4]. Whilst the
specificity of these changes to orbital tissues remains poorly
understood, GO orbital fibroblasts have been shown to exhibit
distinctive Thy-1 [5,6], CD34 [7] and IGF-1 receptor (IGF-1R)
[8] profiles, as well as unique responses to epigenetic factors such
as enhanced chemokine production, adipogenesis and hyaluronan
secretion [3,9]. Thy-1 expression is of particular interest, as it was
shown that segregation of fibroblasts on the basis of Thy-1
expression reflects differences in cell fate - with only Thy-1
negative cells being able to undergo adipogenesis, a key
pathological feature of GO [10]. Thy-1 expression has been
shown to be attenuated in GO fibroblasts, possibly underlying a
pro-adipogenic phenotype [5,6,10].
In addition to the distinctive cell types, there are also unique
anatomical considerations in the orbit that might mediate site-
specific influences. The orbit is a conical compartment, enclosed
by bony wall and a tough anterior orbital septum [11], and any
increase in tissue volumes resulting from inflammatory oedema or
venous congestion can lead to a marked rise in intraorbital
pressure. Direct manometry has shown intraorbital pressure to rise
from 4 mmHg in normal orbits [12] to 27 mmHg in severe GO
[13]. Tissue mechanics is a fundamental process governing cell
proliferation, migration and differentiation [14,15]. Although
tissue tension is known to modulate stem cell differentiation, and
particularly adipogenesis [16], nothing is known about the
mechanobiology of GO, despite marked changes in the mechan-
ical environment of GO fibroblasts during the course of the
disease.
We hypothesised that the disordered mechanical environment
in active GO might underlie some aspects of the pathogenesis of
this condition. We here demonstrate, using a novel in vitro 3D
culture model, that reproducing a physiological environment
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induces a spontaneous Thy-1-dependent adipogenesis in GO
fibroblasts. We also show that GO fibroblasts, as compared to
those from undiseased orbits, are more contractile in a 3D
functional model of fibrosis, and that this difference is not linked to
Thy-1 expression. Finally, we describe how our 3D model can be
used to interrogate potential pathways mediating adipogenesis and
fibrosis and putatively evaluate new treatments for GO.
Materials and Methods
Ethics Statement
This study adhered to the tenets of the Declaration of Helsinki
and was approved by the National Research Ethics Service
Committee London- Bentham (REC reference 11/LO/1170).
The study was explained to potential study participants and
written informed consent was obtained before enrolment.
Clinical Samples
Orbital fat was harvested from 3 patients with active GO
undergoing orbital decompression and from 3 control patients
undergoing removal of subconjunctival fat herniation. The clinical
features of these patient groups are presented in Table 1. The
biopsies were mechanically dispersed and the tissue fragments
placed in tissue culture dishes in Dulbecco’s modified Eagle’s
medium (DMEM) with 4.5g/L l-Glutamine (PAA), supplemented
with 10% foetal bovine serum (FBS, Sigma), 100 IU/ml penicillin,
100 mg/ml streptomycin (Invitrogen) at 37uC with 5% carbon
dioxide. Following growth from the explant, the fibroblast
populations (controls: CO2, CO3, CO4; GO populations: HO1,
HO2, HO3) were trypsinized and maintained routinely in the
above medium. The fibroblast populations were found to be
positive for the mesenchymal marker vimentin, and negative for
cytokeratin and Factor VIII (Methods S1 and Figure S1), as well a
negative for the fibrocyte marker CD45 (Figure S2), confirming
their fibroblast nature [6] [10]. The cells were used between
passage 4 and 9 for all experiments.
Collagen Contraction Assay
The collagen contraction assays were performed as previously
described [17]. GO or control cells were seeded in a 1.5 mg/ml
collagen type-I matrix (First Link (UK), Ltd) at a concentration of
76104 cells/ml, within the coverslip area of a 35 mm diameter
MatTek dish (MatTek Corporation, Ashland). Following poly-
merisation, the gels were detached from the edge of the well, 2 ml
of culture medium were added, and gel contraction was monitored
daily for 7 days by digital photography. Gel surface area was
measured using ImageJ software (http://rsb.info.nih.gov/ij/), and
the contraction expressed as the percentage decrease in gel area
with respect to the original area (day 0). For cytokine stimulation,
the gels were made with 146104 cells/ml in serum free medium
with/without 5 ng/ml recombinant human TGFb1 or 10 ng/ml
IL1b (R&D systems). For the testing of inhibitors, 10 mM Imatinib
(Cayman Chemicals), 10 mM PP2 (Tocris Bioscience) or 5 mg/ml
1H7 (anti-IGF1R antibody, BioLegend) were added to the
medium at day 0 and maintained throughout the assay. For
1H7, the antibody was also incorporated into the gel mix before
polymerization, at a final concentration of 10 mg/ml.
AlamarBlue (Invitrogen, Carlsbad, California) was used to
measure the relative proliferation of the fibroblasts in the collagen
matrices. A 10% v/v Alamar Blue solution was mixed with 2 ml of
the gel contraction assay culture medium at day 0 (1 our after gel
setting), day3 and day 7 and incubated for 24 h. The fluorescence
signal of sample medium from each well was read using peak
excitation and emission wavelengths of 544 nm and 590 nm
respectively (Fluostar Optima, BMG Biotech). Each experiment
was carried out in triplicate and repeated on at least 3 separate
occasions.
Adipogenic Differentiation in Monolayers (2D)
After plating 16105 cells into 35 mm dishes with growth
medium, the cells were allowed to become confluent and
maintained at 100% confluency for 2 days. The medium was
then replaced with Adipocyte Differentiation Medium (ADM,
Zenbio) for a further 3 days, after which the medium was changed
to Maintenance medium and the cultures maintained for a further
2 weeks. Adipogenic differentiation was assessed by Oil-Red-O
staining. Briefly, the cell monolayers were washed in PBS and
fixed for 20 minutes with 10% formalin (Sigma). The monolayers
were washed twice in PBS and once in distilled water, and
incubated with 60% isopropanol for a further 5 minutes. An Oil-
Red-O staining solution was prepared as a 3 mg/ml stock in 99%
isopropanol, diluted 3:2 v/v in distilled water, and filtered
immediately prior to use. After removal of the isopropanol, the
cells were stained with the diluted Oil-Red-O solution for 2
minutes and washed in distilled water until the water ran clear.
Haematoxylin was added for 1 minute, and the cells washed again
in water until it ran clear. Evidence of adipocyte differentiation
(red lipid droplets) was observed with a 10x oil-objective on a Zeiss
Axioplan 200 microscope, the images acquired using the attached
Axioplan MRC camera, and processed in with Adobe Photoshop
software for matching brightness and contrast.
Adipogenic Differentiation in Gels (3D) and Application
of External Pressure
MatTek dishes were washed for 2 minutes with 1 M HCl,
followed by a rinse in 70% ethanol, and a rinse in PBS. The
coverslip area was then coated with 400 mg/ml collagen for 15
minutes, the excess collagen aspirated, and the area allowed to dry.
Table 1. Origin of the samples of orbital fibroblasts.
Cell line Age Gender Condition Duration of GO/months CAS Score
CO2 65 M Orbital fat Prolapse n/a n/a
CO3 68 F Orbital fat Prolapse n/a n/a
CO4 49 M Evisceration n/a n/a
HO1 71 F GO 15 6
HO2 60 M GO 8 5
HO3 57 M GO 6 6
doi:10.1371/journal.pone.0095586.t001
Adipogenesis and Contraction in Graves’ Cells
PLOS ONE | www.plosone.org 2 April 2014 | Volume 9 | Issue 4 | e95586
GO or control cells were seeded into collagen gels within the well
area as for the contraction assay, but the gels were not detached
after polymerization, and 2 ml of medium was carefully added to
the dish so as to not disturb the gel area. The attached gels were
cultured for 5 days, and further left untreated or subjected to
pressure for another 48 hours. An equivalent of 28 mmHg
pressure was generated by layering the gels with a fine sterile fabric
mesh, a 13 mm diameter coverslip, and a custom machined
stainless steel insert weight of 58.5 g (Figure 1). After 2 days’
culture, the medium was removed and replaced with 10%
formalin for 20 minutes, after which the weight, fabric mesh and
coverslip were removed, and the gel left in formalin for a further
20 minutes. Gels were then washed twice in PBS and processed for
Oil-Red-O staining as with the monolayers. The proportion of
Oil-Red-O positive cells was evaluated using a 40x objective on a
Leica DMIL microscope, on at least 100 cells from random fields
for each condition. Cells with more than a couple of lipid droplets
clearly within the cytoplasm were counted as positive. The scoring
was done blind on the actual samples directly under the
microscope, and reproduced by two independent experimentators.
Each experiment was done in triplicate and, unless otherwise
noted, a minimum of 3 experiments were performed for each
condition. For the testing of the inhibitors, 10 mM Imatinib,
10 mM PP2 or 5 mg/ml 1H7 (with 10 mg/ml in the gel) were
added to the medium immediately after gel polymerization (day 0)
and maintained throughout.
Quantitative Real-Time PCR
Gels were placed directly into TRIzol Reagent (Invitrogen) at
4uC for 1hr. Homogenization and phase separation were carried
out according to the manufacturer’s instructions. The aqueous
phase was harvested and used for RNA isolation using the RNeasy
Mini Kit according to the standard protocol (Qiagen). Reverse
transcription was carried out using the QuantiTect Reverse
Transcription Kit (Qiagen) according to manufacturer’s instruc-
tions. PPARg gene expression was measured by q-PCR using the
SYBR Green JumpStart Taq ReadyMix for quantitative PCR
(Sigma-Aldrich, UK) with validated primers. The GAPDH gene
was used as an endogenous control to normalize sample
concentration, and all samples were run as 6 repeats. RT-PCR
reactions were performed on an HT7900 Fast Real-Time PCR
system (Applied Biosystems), and the final analysis was performed
using DART-PCR v1.0 software [18]; the software summarises the
Ct values and calculates the efficiency of amplification for each
data set, in order to generate a relative expression value (R0) that
can be compared across the samples. The R0 values of the gene of
interest are normalised to that of the housekeeping gene for each
sample in order to obtain, across the samples, the ‘‘fold’’ change in
the gene of interest. The 6 replicates for each condition allow for
internal variation and therefore permits any differences to be
statistically significant.
FACS Analysis and Thy-1 Population Sorting
Subconfluent (70–80% confluency) cells were trypsinised,
washed, and a minimum of 300,000 cells per condition were
transferred into 15 ml tubes. Cells were centrifuged and the pellet
re-suspended in 500 ml of either PBS or PBS with primary
antibody (1:20 Anti-Thy-1 clone F15-42-1, Millipore). Cells were
kept on ice for 1 hour with occasional mixing of the tube. Cells
were then washed once in PBS, and further incubated with
secondary antibody (1:50 Alexa fluor 488 Affinipure donkey anti-
mouse IgG (H+L), Stratech) in PBS for 1 hour on ice with
occasional shaking. Cells were washed twice with PBS, re-
suspended in 500 ml of PBS, transferred to a FACS tube (BD
Falcon polystyrene 352052) and analysed on a FACSCalibur
(Becton Dickinson). Between 1 and 2 x104 events were counted for
each sample, and the Geometric Mean fluorescent intensity
(GMFI) evaluated after subtraction of the fraction of positive cells
from the secondary antibody alone. As both control and GO cells
had a dominant proportion of Thy-1-positive cells (albeit differing
in the level of expression), the fraction of cells with low levels of
expression of Thy-1 (fluorescence levels up to 103) was chosen to
calculate the percentage of Thy-1-low expressing cells. The HO2
GO cell line was chosen to separate Thy-1(2) and Thy-1(+)
populations, as it displayed a significant proportion of both
populations. HO2 cells were prepared for FACS analysis as
described above and sorted on a Moflo XDP (Beckman Coulter,
California) at the Institute of Child Health Cytometry Core
Facility (UCL, London). The Alexa Fluor 488 signal was collected
in FL1 channel through a 530/40 bandpass filter. A light scatter
gate was drawn in the FSC versus SSC plot to exclude debris and
clumps and include viable cells. Cells in this gate were displayed in
a SSC versus SSC-W to further target single cells. Single and viable
cells were then analysed in a SSC versus FL1 plot and a final gate
was drawn to collect the labelled cells. A control sample (sham-
treated HO2 cells, HO2s) was processed in an identical manner
(including the journey to the cytometry facility) but not run
through the FACS. Following sorting, the cells were plated in
tissue culture dishes, allowed to recover for 24 hours, and
processed for contraction or adipogenesis analyses within one
passage.
Figure 1. 3D pressure set up. Fibroblasts were embedded into a collagen gel within the well of a Mattek dish (A) and allowed to establish in the
gel for 5 days. Pressure equivalent to pathological levels in GO (28 mmHg) was then applied to the gel by laying a coverslip on top and placing a
weight (B) on it. The pressure set up (C) was maintained for 48 hours and the gels were fixed and processed for staining or RNA extraction.
doi:10.1371/journal.pone.0095586.g001
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Statistical Analysis
All graphs show mean and SEM for at least 3 individual
experiments (unless otherwise noted). Statistical analysis was
performed using Student’s t test.
Results
GO Fibroblasts Display Increased Matrix Contraction
Capability
Orbital fibrosis is a major pathological feature of GO. We have
previously shown that fibroblasts isolated from pro-fibrotic
periocular tissues display increased contractile properties as
compared to normal counterparts [17]. We therefore hypothesised
that the clinically-observed fibro-proliferative nature of GO could
be reproduced using our standard 3D collagen gel contraction
assay [17] [19,20]. Although there was significant variation in each
set (Figure S3A), GO orbital fibroblasts overall contracted collagen
matrices more efficiently than control fibroblasts (Figure 2A). An
Alamar Blue proliferation assay revealed that this increased
contractility may be partly due to a higher proliferation rate for the
GO cells in the gels (Figure 2B), although the proliferation levels
were minimal, with no more than a 1.5 times increase at day 3 and
7 for all cell lines but HO2. In accordance with our previous work
[19], there was overall no correlation between the cell proliferation
rate and their ability to contract the matrix (Figure S3B).
Incidentally, as increased fluorescence in the Alamar Blue assay
signifies higher reduction levels in the environment, the lower
baseline fluorescence levels observed at day 0 for the GO cells
suggest that they intrinsically generate a more oxidative environ-
ment than the control cells, in agreement with a previously
suggested link between GO and oxidative stress[21–23]. A range
of inflammatory cytokines are known to promote fibroblasts
contractile activity, with specific cytokines such as TGFb1 linked
to tissue scarring and fibrosis. To assess whether the increased
contraction potential observed in GO cells following serum
stimulation was linked to a greater sensitivity to inflammatory
cytokines, we performed fibroblast-mediated gel contraction assays
following stimulation with TGFb1 or IL1b, two of the main
cytokines linked to scarring and fibrosis. While control orbital
fibroblasts responded only and poorly to TGFb1, GO cells showed
an increase in gel contraction following both IL1b and TGFb1
stimulation, although the response to TGFb1 was much stronger
(Figure 2C). Neither control, nor GO cells proliferated in the assay
(data not shown). Overall, this data suggested that the GO
fibroblasts display an intrinsic fibro-proliferative phenotype,
consistent with the disease pathology.
GO Fibroblasts Undergo Spontaneous and Pressure-
induced Adipogenesis in 3D Cultures
Another key feature of GO is adipogenesis, where orbital
fibroblasts trans-differentiate into adipocytes [5,6]. To explore
their adipogenic potential, we first determined the cells’ ability to
differentiate into adipocytes in 2D monolayers using standard
biochemical stimulation with a commercially available differenti-
ation medium. As expected [10], even after 2 weeks, control
orbital fibroblasts showed only a limited ability to differentiate into
adipocytes - with a maximum of 37% cells (CO4) mildly positive
for Oil-Red-O (Figure 3, A and D). By contrast, all three GO cell
lines had, on average, more than 40% cells positive for Oil-Red-O,
with most of the positive cells displaying a strong accumulation of
lipid droplets (Figure 3, B–D). To better simulate the pathophys-
iological environment of orbital tissue in the context of active GO,
fibroblasts were embedded in 3D collagen gels that were
maintained attached within the wells for 5 days, so as to allow
the cells to form a tissue-like environment and attain tensional
homeostasis [24]. Custom weights were then placed onto the gels
to increase pressure to the pathological levels measured in patients
with active GO [13] and, after 48 hours, the gels were fixed and
stained with Oil-Red-O or underwent RNA extraction for qPCR
analysis. No significant changes in cell viability or morphology
were identified after the application of pressure, with only a minor
increase in the proportion of dead cells (Figure S4). Unexpectedly,
after 7 days in 3D cultures, most GO fibroblasts spontaneously
differentiated into adipocytes - with at least 60% of the cells
presenting lipid droplets (Figure 4A) and expressing PPARg
(Figure 4B). By contrast, control orbital cells displayed only
minimal differentiation (20% or less Oil-Red-O positive cells and
low PPARg expression levels). Most notably, CO4 cells showed
elevated PPARg levels, matching the significant adipogenesis level
measured in 2D after biochemical differentiation. However, all cell
lines – both GO and control fibroblasts - showed maximum levels
of adipogenesis (both Oil-Red-O staining and PPARg expression)
when cultured under pressure (Figure 4, A and B), with the
controls reaching similar levels as GO cells. This suggests that,
although GO orbital fibroblasts clearly have an intrinsic pro-
adipogenic phenotype, pressure applied to normal orbital fibro-
blasts is sufficient to induce trans-differentiation into adipocytes.
A Thy-1-low Population in GO Cells Underlies the
Adipogenic Phenotype
As Thy-1 expression has previously been shown to define
myofibroblastic or adipogenic phenotypes in myometrial and
orbital fibroblasts [10], we hypothesized that its expression might
be linked to the contractile and/or adipogenic phenotype of GO
cells. FACS analysis revealed that control orbital fibroblasts
expressed high levels of Thy-1, with a small fraction (if any) of
negative- to low-expressors (Figure 5A). By contrast, GO cells
presented significantly lower levels of Thy-1 expression, with a
much lower level of geometric mean fluorescence intensity
(GMFI), and a more spread overall expression pattern (Figure 5,
A and B). While the control cells typically had fluorescence levels
above 103, most GO cells were much below this value (Figure 5 C).
To determine whether a Thy-1-low population in GO was
linked to the observed contractile and adipogenic phenotypes, we
attempted to isolate Thy-1-negative and Thy-1-positive cell
populations to analyse their behaviour separately. We selected
the HO2 GO cell line for this study, as it had the strongest
contractile and adipogenic profiles, as well as a significant number
of both Thy-1-low and Thy-1-high expressing cells. The HO2 cell
line was initially sorted into fully separated Thy-1(2) and Thy-1(+)
populations - comprising cells completely negative or expressing
very low levels of Thy-1 (fluorescence levels 101 to 36102) and cells
expressing Thy-1 at around the peak of fluorescence (fluorescence
levels 103 to maximum), respectively. However, we found that
these sorted populations were extremely unstable and both
reverted to the original mixed phenotype within 1 passage or less.
In an attempt to reduce the instability of the sorted cells, we
adopted less stringent fluorescence selection criteria, defining a
Thy-1-low and a Thy-1-high cell population respectively, com-
prising the cells from negative to about one-third of the maximum
fluorescence (up to 26103; Thy-1-low) or all the cells above two-
thirds of the peak fluorescence (fluorescence levels 36103 to
maximum; Thy-1-high). The populations sorted in this way were
more stable and did not revert back to the original HO2 mixed
phenotype until passage 2 or later. Thy-1-low, Thy-1-high and a
sham-treated HO2 line (labelled but not sorted) were examined for
their contractile and adipogenic behaviour immediately after, or
within 1 passage of sorting. While Thy-1-low cells had a high
Adipogenesis and Contraction in Graves’ Cells
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Figure 2. GO cells contract collagen matrices to a greater extent compared to control cells. (A) Control (red) and GO (blue) cells were
embedded in free-floating collagen matrices in medium supplemented with 10% serum and contraction was monitored daily for 7 days. Contraction
is expressed as the percentage of decrease in the gel area relative to the area at time 0. Shown is mean +/2 SEM for 3 GO (HO1-3) and 3 control (CO2-
4) fibroblast lines with 3–6 experiments in triplicate for each cell line. * Significant difference between GO and control cells, P,0.05. (B) Cell
proliferation during gel contraction as measured using an Alamar Blue assay. Shown is mean +/2 SEM each with 3 experiments in triplicate for each.
*P,0.05, ***P,0.001, significant difference compared to level at day 0. (C) Day6 collagen gel contraction level in response to TGFb1 and IL1b
stimulation in all CO and HO fibroblasts (all normalized to the average Serum Free (SF) sample value for CO cells, n = 3 experiments, mean 6 SEM).
Statistical significance between SF and TGFb1 or IL1b treated samples (*p,0.05, ***p,0.001) in each category; between SF in CO and HO cells ("" P,
0.01), between TGFb1 treated samples of CO and HO cells (??p,0.01), and TGFb1 and IL1b treated samples between CO and HO cells respectively (
NNp,0.01).
doi:10.1371/journal.pone.0095586.g002
Figure 3. GO cells differentiate into adipocytes in monolayer cultures. (A–C) Representative images of orbital fibroblasts (A, Control-CO2; B,
GO-HO1; C, GO- HO3) stained with Oil Red O after 2 weeks culture in adipocyte differentiation medium. Only a small proportion of cells containing a
few lipid droplets were found in CO cells (arrow), while large clumps of highly positive cells (arrowheads) were present in HO cells. (D) Adipocyte
differentiation in control and GO cells. Graph shows the percent of Oil-Red-O positive cells for each cell type (mean +/2 SEM, n = 3–4). DMEM,
standard culture medium; ADM, adipocyte differentiation medium. GO cells overall display significantly enhanced adipogenesis in presence of
differentiation medium compared to control orbital fibroblasts (P = 0.03), and all cell lines show a significant increase in adipogenesis in ADM
compared to regular DMEM (* p,0.05), with the exception of CO4 and HO2.
doi:10.1371/journal.pone.0095586.g003
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adipogenic profile similar to that of sham-sorted parental HO2s
cells, Thy-1-high cells were significantly less adipogenic under
unpressurized conditions (Figure 5D), this implying (as predicted)
that the presence of a Thy-1-low population in GO cells might at
least partly underlie their adipogenic phenotype. By contrast,
when tested for gel contraction potential, neither the Thy-1-low,
nor the Thy-1-high populations were significantly different from
the HO2s cells (Figure 5E) - this suggesting that the contractile
phenotype is not linked to Thy-1 expression.
The Contractile and Adipogenic Phenotypes are
Regulated by Separate Pathways
To further explore the dichotomy between the contractile and
adipogenic phenotypes in GO, we tested three drugs broadly
targeting pathways that could potentially regulate these processes.
Imatinib, a tyrosine kinase inhibitor that targets the Bcr-Abl
pathway as well as c-kit and PDGF-R, has been studied extensively
as a candidate for reducing tissue remodelling in GO, through a
blockade of the PDGF receptor [25,26]. The broad spectrum Src
family kinase (SFK) inhibitor PP2 was used to target SFKs, as
SFKs have been implicated in adipogenesis [27,28] and their
expression is reduced in Thy-1 positive cells [29,30]. PP2 was
confirmed to block serum-mediated Src phosphorylation in GO
cells (Figure S5A). Finally, we used the commercially available
1H7 antibody against the IGF-1 receptor, as the IGF-1 receptor is
over-expressed in GO fibroblasts [31,32] and data, including our
own (Figure S5B), suggests that this antibody can reverse some of
the clinical features of GO such as hyaluronan production [9,33].
All 3 inhibitors significantly reduced gel contraction, by about
50% at day 7 (Figure 6A). However, 1H7 had no effect on
adipogenesis (Figure 6B) - either with or without pressure - and
Imatinib actually increased adipogenesis, with all treated cells
displaying a massive accumulation of Oil-Red-O stained droplets
(Figure 6C). In contrast, PP2 treatment significantly inhibited
spontaneous adipogenesis in 3D, and also showed a tendency to
reduce the pressure-induced adipogenesis (although the latter was
not significant; Figure 6B). Overall, this suggested that, whilst
contraction and adipogenesis are clearly regulated in part by
separate pathways, both pathways may be modulated through
common upstream SFK signalling.
Discussion
One characteristic feature of GO is the occurrence of both
adipogenesis and fibrosis as simultaneous pathological processes.
The ability of GO fibroblasts to differentiate into adipocytes has
been widely described [3,5,6,10,34], but little is known about their
fibrotic potential. Using our well-characterised 3D model of
collagen contraction, we have previously shown that fibroblasts
derived from fibrotic ocular tissues display an increased contractile
phenotype as compared to controls, and these fibroblasts retain,
in vitro, both altered biomechanical properties and a specific
molecular signature that might underlie their behaviour in disease
[17]. Here we have uncovered a similar feature for orbital
fibroblasts from patients with active Graves’ orbitopathy, suggest-
ing that these cells have acquired an intrinsic fibro-proliferative
phenotype and increased sensitivity to inflammatory cytokines.
Whilst standard chemical stimulation of cellular monolayers
confirmed the greater adipogenic potential of GO fibroblasts as
compared to controls cells, we have shown that, unexpectedly,
active GO fibroblasts spontaneously undergo adipogenic differen-
tiation, without the need for any chemical stimulation, when
placed in a pseudo-physiological 3D environment [24,35,36],
suggesting that these cells are intrinsically primed for adipogenesis.
We further demonstrated, using our pressure model, that healthy
orbital fibroblasts - which normally do not spontaneously
differentiate into adipocytes - can be induced to display a full
adipocyte phenotype as a result of pressure stimulus alone. This
suggests that the pathological intraorbital pressures encountered in
GO [13] could be driving adipogenesis, potentially explaining
clinical results suggesting that orbital decompression can contrib-
ute to a decrease in disease activity [37].
Although both fibrosis [38] and adipogenesis [16,39] are
influenced by mechanical cues, these two processes are usually
mutually exclusive [16]. To explain the unusual co-occurrence of
these two processes in the Graves’ orbit, we postulated that orbital
fibroblasts might comprise a mixed cell population and further
investigated the expression of Thy-1 as a marker that might
differentiate the phenotypes [6]. In accordance with previous
findings [6,40], we identified a subpopulation of Thy-1-low
expressors in our GO fibroblast lines, and showed that this
population likely underlies the adipogenic phenotype of the GO
cell lines. Interestingly, strict separation of the Thy-1 positive and
the Thy-1 negative populations rendered them very unstable -
reverting back to their original mixed phenotype within one
Figure 4. GO cells spontaneously differentiate into adipocytes
in 3D cultures. Control (CO2-4) or GO (HO1-3) cells were seeded into
collagen gels and cultured for 5 days in standard culture medium. The
gels were then left untreated (0 mmHg) or subjected to pressure
(28 mmHg) for a further 48 hours, followed by (A) fixation and staining
with Oil-Red-O or (B) RNA extraction and qPCR. (A) Adipocyte
differentiation in control and GO cells, shown as the percent of Oil-
Red-O positive cells in each cell line (mean +/2 SEM, n= 3). Student’s t
test was used to compare adipogenesis levels between no pressure and
pressure for each cell line (* p,0.05, ***p,0.001), and between control
cells and GO cells overall (significantly different under no pressure
condition, p = 0.001). (B) PPARg expression (normalised to GAPDH,
levels) as measured by q-PCR. Shown is the mean +/2 SEM for 3
experiments (* p,0.05, ** p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0095586.g004
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passage. A previous study used multiple rounds of magnetic bead
separation to successfully isolate the Thy-1(+) and Thy-1(2)
populations, which might have influenced the stability of their
phenotype [40]. Alternatively, the instability might be related to
Figure 5. A Thy-1-low cell population in GO cells underlies the adipogenic, but not the contractile phenotype. (A) Expression levels of
Thy-1 (CD90) protein were determined in control (CO2-4) and GO (HO1-3) cells by FACS analysis. Shown is a representative distribution for each cell
line (from a minimum of 3 experiments), where white shows the baseline control distribution (IgG isotype control antibody), and grey depicts the
Thy-1 expression profile (% Thy1 positive cells as indicated). (B) The Geometric Mean Fluorescent Intensity (GMFI) and (C) the proportion of Thy 1-low
cells (fluorescence ,1000) are represented as mean +/2 SEM, from three independent experiments for each cell line. Statistical analysis using a
Student’s t test shows a significant difference between control and GO fibroblasts for both parameters (p as indicated). (D, E) HO2 cells were FACS-
sorted into Thy-1 negative/low expressor (Thy-1-low) and Thy-1 strongly positive (Thy-1-high) populations, or sham sorted (HO2s), and tested for
their ability to differentiate into adipocyte in 3D (D), and to contract collagen matrices (E), immediately and/or within 1 passage after sorting. (D)
Adipocyte differentiation: graph shows the percent of Oil-Red-O positive cells for each cell type (mean +/2 SEM; HO2 and Thy-1-high n= 3, HO2s and
Thy-1-low, 1 experiment in triplicates). ** significant difference between HO2 and Thy-1-high (p = 0.01). (E) Thy-1-low and Thy-1-high cells collagen
matrix contraction at day7, relative to sham-sorted HO2 cells (mean +/2 SEM for at least 3 experiments in triplicate for each cell line, no significant
difference between the control and sorted cells).
doi:10.1371/journal.pone.0095586.g005
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the sample origin, our tissues being derived from patients with
extremely severe and active Graves’ orbitopathy. Sample origin
might also explain the contradictory findings in another study
where - using samples from patients with less severe disease - the
authors showed enhanced Thy-1 expression in GO fibroblasts,
rather than a decreased expression [5]. Despite Thy-1 expression
having previously been linked to the contractile phenotype
[29,38], we could not show any difference in contractile efficiency
between Thy-1-low or Thy-1-high cells - indicating that, while
Thy-1 expression might govern adipogenic differentiation, it has
no impact on the contractile phenotype.
Using 3 drugs previously reported as targeting pathways with
therapeutic potential in GO, we showed that our 3D gel model
could be used as an in-vitro drug assay for contraction and
adipogenesis in GO. Significant evidence has implicated IGF1-R
in the pathogenesis of GO [32,41] and IGF-1 induces hyaluronan
synthesis in GO fibroblasts [9], as well as cytokine responses
[42,43]. Identification of the co-localisation of the receptors for
TSH and IGF-1 further supports the targeting of IGF-1 signalling
as a potential treatment for GO [44], and a multicentre trial of an
IGF-1R inhibitor in GO is currently recruiting [45]. We found no
effect of IGF-1R inhibition on adipogenesis, but significant
Figure 6. The contractile and adipogenic phenotypes are regulated by separate pathways. HO2 GO fibroblasts were embedded in
collagen gels for either standard contraction assay (A) or 3D adipogenesis (B, C) in the presence of Imatinib (10 mM), PP2 (10 mM) or 1H7 (10 mg/ml in
gel; 5 mg/ml in medium) inhibitors. (A) Collagen gel contraction in the presence of inhibitors (mean +/2 SEM, for 3 experiments, each in triplicate). ***
significant difference between control and treated samples, p,0.001. (B) Effect of inhibitor treatment on spontaneous adipogenesis in 3D, with/
without pressure. Graph shows the frequency of Oil-Red-O positive cells in treated samples as ratioed to the proportion of positive cells in matching
untreated control samples (mean +/2 SEM, for 3 experiments, each in triplicate). ** significant difference between control and treated samples,
p = 0.03. (C) Representative Oil-Red-O staining of HO2 cells in 3D gels, showing spontaneous adipogenesis upon pressure application (Control
28 mmHg). Treatment with Imatinib resulted in a further increase in the amount of lipid droplets in virtually all cells whether the samples were
unpressured (Imatinib 0 mmHg) or under pressure (Imatinib 28 mmHg).
doi:10.1371/journal.pone.0095586.g006
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attenuation of the contractile phenotype - suggesting that IGF-1R
antagonists might target the proliferative/fibrotic component of
GO. PDGF inhibitors, including Imatinib, have also been
suggested as a possible treatment, as inhibition of this pathway
also reduce hyaluronan synthesis [25,26,46]. We show that, whilst
PDGF-R inhibition was effective at reducing contraction, it
resulted in an unanticipated and exaggerated adipogenic response
in GO fibroblasts - as previously reported [47]. These untoward
effects might limit further exploration of Imatinib as a treatment
for GO. Although SFKs have not so far been directly linked to
GO, SFKs have been linked to both adipogenesis and Thy-1
expression [27–30]. We show here that a broad spectrum SFK
inhibitor alters both the contractile and the adipogenic potential of
GO fibroblasts. Interestingly, SFK inhibition also shows a
tendency towards reducing pressure-induced adipogenesis, which
might indicate an effect on some components of the biomechanical
pathway. Overall these results show that the adipogenic and the
contractile phenotype of GO cells are – at least in part - mediated
through separate pathways as some inhibitors affect only one of
the two processes, but that they both may be regulated through a
common upstream pathway involving SFKs.
Although significant progress has been made in developing
animal models for GO [48,49], these have still not been shown to
have reproducible validity. The development of functional in vitro
test models for GO might, therefore, provide an economical
alternative on the translational pathway from basic science to
therapeutic interventions. We have demonstrated that GO orbital
fibroblasts display an intrinsic dual adipogenic/fibrotic phenotype,
and marked sensitivity to the mechanical environment in a three-
dimensional matrix. The novel three-dimensional cell culture
provides an environment of more physiological relevance, this
facilitating further exploration of the mechanisms and pathogen-
esis of GO – a disease fundamentally associated with gross
disturbance of the mechanical micro-environment.
Supporting Information
Figure S1 Control and GO orbital fibroblasts express
classical orbital fat fibroblast markers. Immunocytochem-
istry for vimentin, cytokeratin and Factor VIII was performed on
cytospins of control (CO2-4) and GO (HO1-3) cells using standard
methods, and the slides were counterstained with H&E staining.
Both sets of orbital fibroblasts were positive for mesanchymal cell
marker vimentin, largely negative for epithelial marker cytokeratin
and fully negative for endothelial marker Factor VIII.
(TIF)
Figure S2 Control and GO orbital fibroblasts do not
express CD45 fibrocyte marker. FACS analysis was
performed on control (CO2-4) and GO (HO1-3) for the fibrocyte
marker CD45, with all cell lines showing a complete absence of
staining for the marker.
(TIF)
Figure S3 Orbital fibroblast matrix contraction poten-
tial is not correlated to cell proliferation in the gels. (A)
Individual contraction curves for control (CO2-4, red) and GO
(HO1-3, blue) fibroblasts in the standard collagen gel contraction
assay. Each curve shows the mean +/2 SEM for 3–6 individual
experiments, each in triplicate. (B) Representation of the gel
contraction at day 3 and day 7 as a function of the proliferation
rate (normalised to the value at day 0) demonstrates an absence of
correlation between the two parameters. Each point represents
one individual cell line at day 3 (red) and 7 (green), with a
minimum of 3 experiments for each. The linear trends at day 3
and day 7 are shown with corresponding R2 value. The overall
correlation coefficient between gel contraction and proliferation
for all data points (day3 and 7 together) is 0.35.
(TIF)
Figure S4 Cell viability in attached gels under pressure.
Control CO4 and GO HO1 fibroblasts were seeded in attached
collagen gels as per our standard 3D adipogenesis protocol with 0
or 28 mmHg applied at day 5, and a LIVE (green)/DEAD (red)
cytotoxicity assay was performed at day 7. Only a minor
proportion of the cells were dead after 7 days in the gels without
pressure (0 mmHg), with no difference between control and GO
cells. There was a small increase in the proportion of dead cells in
the samples that were under pressure for 48 hrs (28 mmHg),
although only mildly significant in control cells (P as indicated on
graph). There was no significant difference in the proportion of
dead cells in control and GO cells under pressure. Arrows on the
images point to dead cells.
(TIF)
Figure S5 Activity of PP2 and 1H7 inhibitors on GO
cells. (A) SFK inhibitor PP2 blocks serum-induced Src phos-
phorylation in GO fibroblasts. HO2 cells were starved ON and
stimulated with 15% serum in the presence/absence of 20 uM
PP2. Shown is a representative Western blot for phosphorylated
Src at time 0, 5 and 30 min after serum stimulation. GAPDH was
used as the loading control. (B) 1H7 anti-IGF-1R antibody blocks
IGF-1 induced hyaluronan (HA) secretion by GO fibroblasts.
HO1 GO cells were starved overnight in medium with 1% serum,
and further incubated for 48 hrs in presence/absence of rIGF-1
(10 nM/L) with/without 1H7 antibody (5ug/ml). The amount of
HA produced by the cells was measured by ELISA and normalised
to cell numbers determined by Alamar Blue Assay. IGF-1
treatment results in a significant increase in HA production (P,
0.001), which is inhibited by treatment with 1H7 (P,0.001).
Shown is an average of 3 experiments, each in triplicate.
(TIF)
Methods S1.
(DOCX)
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